Status:
COMPLETED
The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome
Lead Sponsor:
Korea University Anam Hospital
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Pioglitazone and rosiglitazone are used in the treatment of diabetic patients. Thiazolidinediones increase insulin sensitivity and show favorable effect blood glucose levels and lipid profiles. The ef...
Eligibility Criteria
Inclusion
- Patients with at least 3 metabolic syndrome criteria of Asian-Pacific ATP III guideline: fasting blood glucose ≥ 110 mg/dl, systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, triglyceride ≥ 150 mg/dl, HDL-cholesterol \< 40 mg/dl for men and \< 50 mg/dl for women.
- Age: 18 years and above
Exclusion
- Hypertensive patients with the use of ACE inhibitor or ARB
- Hyperlipidemic patients with the use of statin or fenofibrate
- Patients with any contraindications to the treatment of thiazolidinediones
- Pregnant or lactating patients
- Chronic alcohol or drug abuse
- Hepatic dysfunction
- Renal dysfunction
- Heart failure (EF \< 50%)
- Expected life expectancy of \< 1 year
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00314561
Start Date
May 1 2006
End Date
December 1 2006
Last Update
July 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Anam Hospital
Seoul, Seoul, South Korea, 136-705